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Abstract
We investigated the promoter polymorphisms of the pituitary growth hormone gene (GH1) and exon 3 deletion polymorphism
(GHRd3) in its receptor gene (GHR) in 299 angiographically proven patients with coronary artery disease (CAD) and 231
asymptomatic controls enrolled in the ongoing Indian Atherosclerosis Research Study. Real time PCR based analysis of the
GHR variant showed significant association of the GHRd3 deletion allele with CAD (OR 0.48, 95% CI: 0.30–0.76, P =
0.0014) and a dominant model of inheritance (Akaike information criterion = 482). The deletion allele showed significant
association with high plasma HDL-c levels (P = 0.001). Sequencing of the proximal promoter region of GH1 revealed 12
novel polymorphisms and a TAGA haplotype constituted by the functional SNPs rs2005171, rs11568828, rs2005172 and
rs6171, that showed significant association with CAD alone (adjusted OR of 3.31 (95% CI = 1.33–8.29, P = 0.011) and in
CAD patients with diabetes (P = 0.019). Mean standardized height was associated with three of the four haplotype-tagging
SNPs in the cohort (P ≤ 0.03). Eleven of the 12 polymorphic promoter SNPs contributed to 14.7% of variation in height in
females in the whole dataset (P = 0.029). CAD patients with history of stroke exhibited marginally significantly lower mean
height as compared to rest of the cohort (P < 0.006). In conclusion, genetic polymorphisms in the GHR gene and its ligand,
GH1, may modulate the risk of CAD in the Asian Indian population.
[Maitra A., Shanker J., Dash D., Sannappa P. R., John S., Siwach P., Rao V. S., Sridhara H. and Kakkar V. V. 2010 Polymorphisms in the
pituitary growth hormone gene and its receptor associated with coronary artery disease in a predisposed cohort from India. J. Genet. 89,
437–447]
Introduction
The growth hormone (GH)-insulin-like growth factor (IGF1)
axis that influences postnatal growth encompasses a multi-
tude of genes that regulate complex diseases including devel-
opmental disorders, ageing, cancer, cardiovascular diseases
(CVD) and their comorbidities (Rodriguez et al. 2007). The
pituitary growth hormone plays a critical role in postnatal
development (Garcia-Aragon et al. 1992). The discovery of
‘fetal programming’ that relates to the influence of adverse
fetal environment on development of metabolic and CVD
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during adult life (Barker 1995) has brought an intriguing
twist to our understanding on the expansive role of the hu-
man GH. Recent studies suggest that GH deficiency can lead
to the development of atherosclerosis by influencing vas-
cular reactivity and by regulating cardiac growth and func-
tion (Cittadini et al. 1994; Climent et al. 2006). Administer-
ing recombinant growth hormone in children with GH de-
ficiency (GHD) (Minczykowski et al. 2005) and in patients
with chronic heart failure (Le Corvoisier et al. 2007) results
in improved cardiovascular parameters and reverses early
atherosclerotic changes in adult GH-deficient men (Pfeifer
et al. 1999a). Short stature has been associated with elevated
blood pressure (Langenberg et al. 2005) and increased risk
of atherosclerosis (Reed et al. 1988). Studies suggest a pos-
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sible link between GH, stature and arterial function (Horan et
al. 2006). An inverse relationship between adult height and
risk of hypertension, and stroke has been reported (McCar-
ron et al. 2000; Song et al. 2003), with involvement of the
GH1-IGF1 growth axis (Bondanelli et al. 2006).
The proximal promoter region of GH1 gene, which en-
codes the pituitary growth hormone, is highly polymorphic
and contains at least 15 well-described single nucleotide
polymorphisms (SNPs) (Horan et al. 2003). Over 40 diﬀer-
ent haplotypes have been identified, some of which are as-
sociated with altered reporter gene expression. By applying
haplotype partitioning, 6SNPs were determined as major de-
terminants of GH1 gene expression (Horan et al. 2006). They
also identified three haplotypes in the locus control region
(LCR), located upstream of the GH1 gene, that enhances the
promoter activity up to nearly 2.8-fold.
The downstream eﬀect of GH1 is initiated by the binding
of circulating GH1 molecules to its cellular receptor, encoded
by the GHR gene, followed by STAT-1 mediated cell sig-
nalling that ultimately stimulates the GH-IGF axis. A copy
number variation of exon 3 of GHR has been shown to in-
fluence response to GH therapy in children with idiopathic
short stature (Ko et al. 2009) and other developmental ab-
normalities (Jensen et al. 2007; Binder et al. 2008) with bet-
ter hormonal response seen in patients carrying the exon 3
deletion allele. However, there have also been reports to the
contrary (Blum et al. 2006; Carrascosa et al. 2008). Multiple
reports have implied that the truncated gene product might
be associated with enhanced cell signalling initiated by the
GH-GHR binding, which leads to diﬀerential stimulation of
the GH-IGF axis. Considering the pleiotropic eﬀect of pitu-
itary GH on CVD risk, the objective of the present study was
to explore the genetic variations of GH1 promoter and GHR
genes in the context of a hitherto untested Asian Indian co-
hort with high predisposition to CAD and stroke.
Materials and methods
Study population
Participants selected from the ongoing Indian Atherosclero-
sis Research Study (IARS) were recruited from Bangalore
and Mumbai, located in southern and western India, respec-
tively. The inclusion criteria for the 299 CAD patients were
as follows: diagnosis by echocardiogram and/or coronary an-
giography, surgical treatment by percutaneous transluminal
coronary angioplasty or bypass graft, age at onset ≤ 60 and
≤ 65 years for men and women, respectively, and presence
of strong family history of CVD. A total of 231 healthy vol-
unteers who were asymptomatic for CAD and did not have a
family history of CVD were enrolled from the population and
served as controls. ECG was performed for all controls and
only those with normal ECG were included for the study. All
participants were free from concomitant infections. Blood
samples were collected from study participants by informed
voluntary consent. The study was approved by the institu-
tional ethics committee and was according to the guidelines
of the Indian Council of Medical Research (ICMR) (Ku-
mar 2006) and Helsinki Declaration for Medical Research on
Human Subjects (World Medical Association declaration of
Helsinki 1997). The study was estimated to have 92% power
to detect 1.5-fold change in risk allele frequency given 40%
frequency of the risk allele and type 1 error probability of
0.05.
Anthropometric measurements and lipid assays
Height and weight were measured while body mass in-
dex was calculated. Prevalence of diabetes and hyperten-
sion were ascertained based on self-report of physician’s di-
agnosis and/or use of prescription medications. Plasma and
serum were stored as aliquots at −80◦C and genomic DNA
was isolated from blood pellets using the salting out pro-
cedure (Miller et al. 1988). Plasma total cholesterol (TC)
and triglyceride (TG) were measured using reagents and
standards from Randox laboratories (Crumlin, UK) while
reagents from Bayer diagnostics (Newbury, UK), controls
from Randox (Crumlin, UK) and standards from Dade
Behring Ltd (Milten Keynes, UK) were used to assay for
high-density lipoprotein-cholesterol (HDL-c). Low-density
lipoprotein-cholesterol (LDL-c) was calculated by Fried-
wald’s formula (Johnson et al. 1997) for samples with TG
value less than 400 mg/dL (Friedewald et al. 1972). The
inter-assay coeﬃcient of variation (CV) for the commercial
controls and normal serum pool ranged from 4.9% to 7.0%
for TC, 6.1% to 7.7% for TG and 7.1% to 12.2% for HDL-c.
Sequencing of the GH1 promoter region
The 878 base pair (bp) region of the proximal promoter
region of GH1 gene was amplified from genomic DNA
samples in 283 cases (214 men, 69 women) and 206 con-
trols (135 men, 71 women) using oligonucleotide primers
271F (5′ -GTGTCTCTGCTGCAAGTCCAA) and 1148R
(5′-CATGGCGATACTCACATTCAGAA) and True Allele
PCR Mix in 9700 PCR instrument (Applied Biosystems,
Foster City, USA). PCR conditions: 95◦C for 12 min, 35 cy-
cles of 95◦C for 1 min, 60◦C for 30 s, 72◦C for 1 min and
a final hold at 72◦C for 10 min. PCR products were purified
by ExoSAPit digestion (Amersham Biosciences, Piscataway,
USA), sequenced bidirectionally using PCR primers and Big
Dye Terminator v 3.1 sequencing kit from ABI as per man-
ufacturer’s recommendations and analysed in 3130XL au-
tomated genetic analyzer (Applied Biosystems, Foster City,
USA). Sequence data were compared with reference se-
quence downloaded from Ensembl Genome Browser release
44-April 2007 (Hubbard et al. 2007) and screened for se-
quence polymorphisms with SeqScape v 2.5 software (Hub-
bard et al. 2007).
Copy number variation of GHRd3
Detection of variation in copy number of exon 3 deletion
of the GHR gene (GHRd3) was performed by real time
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PCR in ABI 7500 Real Time PCR system (Applied Biosys-
tems, Foster City, USA) based on previously described
method (Horan et al. 2006). Briefly, the exon 3 genomic re-
gion was amplified using oligonucleotide primers, GHRX3F
(5′ - TCTGTTTCAGCCACAGCAGCTA) and GHRX3R
(5′- TGTCTTTAGGCCTGGATTAACACTT) using SYBR
Green I PCR Master mix (Applied Biosystems, Foster City,
USA). PCR conditions: 50◦C for 2 min, 95◦C for 10 min and
40 cycles of 95◦C for 15 s, 60◦C for 1 min followed by disso-
ciation curve analysis to confirm the specificity of PCR am-
plification. Exon 10 of GHR was simultaneously amplified as
endogenous control with oligonucleotide primers GHRX10F
(5′ - CCCAGGTGAGCGACATTACA) and GHRX10R (5′
- CATCCCTGCCTTATTCTTTTGG). Calculation of copy
number of GHRd3 allele was performed by relative quan-
titation approach using exon 10 as endogenous control and
based on specific assay eﬃciencies (Pfaﬄ 2001). Individuals
homozygous for full length GHR and exon 3 deleted GHR
genes would have zero and two copies of GHRd3 allele re-
spectively, while heterozygous individuals would have one
copy of the deletion allele.
Statistical analysis
Deviation from Hardy–Weinberg proportions was assessed
by χ2 test. Correspondence analysis was performed us-
ing Minitab v14 (Minitab, Pennsylvania, USA) (Greenacre
1984) to assess the contribution of GH1 promoter SNPs to
genetic variability in the dataset. Estimation of significant
diﬀerences in the distribution of GH1 promoter genotypes
and GHRd3 deletion polymorphism between cases and con-
trols, haplotype analysis and estimation of odds ratio (OR)
was performed by logistic regression analysis with SNPStat
online software tool and Haploview v 4.0 software (Barrett
et al. 2005; Sole et al. 2006). The percentage of population
attributable risk (PAR) was estimated by Winpepi (Abram-
son 2004). Routine statistical analysis was carried out with
SPSS v 17 software (SPSS, Chicago, USA). All quantitative
values are represented as mean ± standard error (s.e.). Dif-
ferences in group means for age, BMI, height, waist–hip ra-
tio, systolic and diastolic blood pressure were assessed by
2-tailed Student t-test. Normality of plasma HDL-c levels
was assessed by Kolmogorov–Smirnov test and Q–Q plots,
and data were log-transformed for normalization. Analysis of
variance was performed to assess the association of CAD and
stroke with standardized height (height Z-score) and GH1
promoter genotypes and GHRd3 allele copy number with
plasma HDL-c levels with and without adjustment for sig-
nificant clinical covariates. Linear regression analysis was
performed to assess the significant promoter SNPs that con-
tributed to standardized height. A nominal P value of 0.05 or
less was considered as statistically significant.
Results
Clinical characteristics
Detailed clinical characteristics of study cohort are provided
in table 1. A total of 530 subjects comprising of 299 CAD
patients and 231 control subjects were enrolled in the study.
The mean age at onset of CAD was 45.58 ± 0.58 years and
51.59 ± 0.92 years in men and women, respectively. Over 42
Table 1. Clinical characteristics of the study participants.
Control Case
Description (n = 231) (n = 299) P value
Age 47.4 ± 0.48 50.68 ± 0.50 0.001
Gender (M/F) 156/75 227/72 0.032
BMI(kg/m2) 25.23 ± 0.28 26.18 ± 0.24 0.011
Height(cm) 162.01 ± 0.58 163.25 ± 0.48 0.098
Weight(kg) 66.17 ± 0.85 69.8 ± 0.66 0.001
Waist/Hip Ratio 0.92 ± 0.01 0.95 ± 0.003 < 0.0001
Systolic Blood Pressure (mm Hg) 121.66 ± 1.17 125.65 ± 0.99 0.009
Diastolic Blood Pressure (mm Hg) 80.80 ± 0.65 81.38 ± 0.50 0.476
Hypertension (%) 22 (9.6) 175 (58.5) < 0.0001
Diabetes (%) 11 (4.8) 132 (44.1) < 0.0001
Smoking (ever) 59 (25.8) 124 (41.6) < 0.0001
Statin (%) – 202 (71.1) –
Total Cholesterol (mg/dL) 184.8 ± 2.39 156.08 ± 2.53 < 0.0001
Triglycerides (mg/dL) 167.7 ± 7.98 163.33 ± 4.4 0.613
HDL Cholesterol (mg/dL) 45.86 ± 0.76 37.34 ± 0.50 < 0.0001
LDL Cholesterol (mg/dL) 107.52 ± 2.06 85.12 ± 1.93 < 0.0001
Data are shown as mean ± SEM. Diﬀerences in mean values for continuous traits (age,
BMI, height, weight WHR, systolic blood pressure, diastolic blood pressure, all lipids)
were tested by student t-test; Diﬀerences in frequency distribution for discrete vari-
ables (gender, hypertension, diabetes, smoking) were tested by chi square test. HDL
cholesterol, high density lipoprotein cholesterol; LDL cholesterol, low density lipopro-
tein cholesterol; SEM, standard error of mean.
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men and 8 women had a history of stroke, 122 men and 53
women had hypertension, while 92 men and 40 women had
diabetes, among the cases. Mean values of BMI, waist–hip
ratio and systolic blood pressure were found to be signifi-
cantly higher in cases as compared to the controls (P < 0.01).
Analysis of GH1 promoter polymorphisms
The 878-bp region of the GH1 gene promoter that was se-
quenced in the present study harboured 16 single nucleotide
polymorphisms (SNPs) which have been previously reported
in the dbSNP. Table 2a describes the allele frequency of the
16 dbSNP SNPs while table 2b provides details on frequency
of the homozygous (1,1 and 2,2) as well as heterozygous
genotypes for cases and controls (table 2). In addition, we
also identified 12 novel sequence variants that have been sub-
sequently submitted to the dbSNP (see table 1 in electronic
supplementary material at http://www.ias.ac.in/jgenet).
Four of the 16 dbSNP variants (rs2005170, rs7219235,
rs2727338, rs11568827) were not polymorphic in our co-
hort, or showed a very low minor allele frequency (1%)
and therefore excluded from further analysis. Of the 12
polymorphic variants in the dbSNP, four SNPs: rs2005171,
rs11568828, rs2005172 and rs6171 constituted the most in-
formative markers with respect to our cohort. A schematic
diagram of the 12 polymorphic SNPs spanning the proximal
promoter region of GH1 has been shown in figure 1 with the
arrow below denoting the negative stand along with the nu-
cleotide positions at 5′ (at SNP rs2011732) and 3′ (at SNP
position rs2001345) regions.
The linkage disequilibrium (LD) structure for the 12
polymorphic SNPs have been shown in figure 1 of electronic
supplementary material. Using correspondence analysis it
has been shown that SNPs rs1811081 (ID #2), rs2011732
(ID #3), rs2005171 (ID #4), rs2005172 (ID #8) and rs6171
(ID #10) included in the first two components, contributed
to 89% of the genetic variability in our cohort (see figure
2; table 2 a,b in electronic supplementary material). The
four most informative SNPs constituted a promoter haplo-
type, TAGA, which was significantly associated with CAD
in the overall data analyses (OR 2.84, 95% CI: 1.04–7.77,
P = 0.043) (table 3). This association remained significant
after adjustment for age, gender, diabetes and hypertension
(OR = 3.31, 95% CI: 1.33 8.29, P = 0.011). Subsequent
analysis of CAD cases with diabetes (n = 123) against non-
diabetic, nonCAD controls (n = 198) showed an OR of 3.52
(95% CI 1.24–10.01, P = 0.019), while similar analysis on
hypertensive CAD patients (n = 166) versus nonhyperten-
sive, nonCAD controls (n = 192) was not statistically signif-
icant (OR of 2.79; 95% CI 0.99 7.88, P = 0.054) (table 3).
Analysis of GHRd3 variant
There was a significant diﬀerence in the distribution of copy
number of exon 3 deletion allele, GHRd3, between CAD
cases and controls (P < 0.0001) with relatively lower fre-
quency of the two copy numbers among cases as compared to
the controls (table 4). Assessment of diﬀerent genetic mod-
els suggested a dominant inheritance model (P < 0.0014)
Table 2a. Allele frequency of the GH1 gene promotor SNPs in the study cohort.
Ancestral Polymorphism Frequency Frequency
allele in the present of allele of allele
SNP∗ dbSNP (1) cohort 1 2
rs2005170 A>G A G>A 1.0 0
rs1811081 G>T G∗ G>T 0.88 0.12
rs2011732 G>T G G>T 0.88 0.12
rs2005171 A>G>T G∗ G>T 0.75 0.25
rs7219235 A>G G G 1.0 0
rs2727338† A>G A T>C 1.0 0
rs11568828† C>T T A>G 0.96 0.04
rs2005172 G>T G T>G 0.67 0.33
rs11568827† − >C G∗ G 1.0 0
rs6171 A>G A A>G 0.75 0.25
rs695 A>C>T A∗ A>T 0.97 0.03
rs6175 C>G G G>C 1.0 0
rs9282699 A>G A A>G 0.99 0.01
rs6172 A>C A A>C 0.99 0.01
rs6173† A>C>G T∗ T>G 0.99 0.01
rs2001345† C>T A∗ A>G 1.0 0
1 denotes the ancestral allele and 2 denotes the mutant allele based on NCBI SNP
database. ∗Where information on ancestral allele is not available in the NCBI SNP
database, we have considered the more frequent allele in our cohort as the ancestral
allele. †SNPs present on the negative strand.
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Table 2b. Genotype frequency of the GH1 gene promotor SNPs in the study cohort.
SNP∗
(chromosome
position)
Genotype (1, 1) Genotype (1, 2) Genotype (2, 2)
n (%) n (%) n (%)
Polymorphism Case Control Total Case Control Total Case Control Total
rs2005170 G>T 489 (1.0) 0 0(61996571)
rs1811081 G>T 219 (0.78) 159 (0.78) 378 (0.78) 59 (0.21) 40 (0.2) 99 (0.20) 4 (0.01) 5 (0.02) 9 (0.02)0(61996506)
rs2011732 G>T 221 (0.78) 159 (0.77) 380 (0.78) 58 (0.2) 43 (0.21) 101 (0.21) 4 (0.01) 4 (0.02) 8 (0.01)(61996499)
rs2005171 G>T 164 (0.58) 121 (0.59) 285 (0.58) 90 (0.32) 71 (0.34) 161 (0.33) 29 (0.1) 14 (0.07) 43 (0.09)(61996476)
rs7219235 C>T 489 (1.0) 0 0(61996425)
rs2727338 T>C 487 (0.99) 2 (0.01) 0(61996366)
rs11568828 A>G 267 (0.94) 187 (0.91) 454 (0.93) 16 (0.06) 19 (0.09) 35 (0.07) 0(61996273)
rs2005172 T>G 131 (0.46) 95 (0.46) 226 (0.46) 113 (0.4) 88 (0.43) 201 (0.41) 39 (0.14) 23 (0.011) 62 (0.13)0(61996255)
rs11568827 G>- 489 (100.0) 0(61996231)
rs6171 A>G 169 (0.6) 119 (0.58) 288 (0.59) 83 (0.29) 73 (0.35) 156 (0.32) 31 (0.11) 14 (.07) 45 (0.09)(61996204)
rs695 A>T 263 (0.94) 193 (0.95) 456 (0.94) 18 (0.06) 10 (0.05) 28 (0.057) 1 (0) 1 (0.003)(61996199)
rs6175 G>C 281 (0.99) 204 (0.99) 485 (0.99) 2 (0.01) 2 (0.01) 4 (0.01) 0(61996196)
rs9282699 A>G 275 (0.97) 203 (0.99) 478 (0.98) 8 (0.03) 3 (0.01) 11 (0.02) 0(61996183)
rs6172 A>T 275 (0.97) 203 (0.99) 478 (0.98) 8 (0.03) 3 (0.01) 11 (0.02) 0(61996174)
rs6173 T>G 275 (0.97) 204 (0.99) 479 (0.98) 8 (0.03) 2 (0.01) 10 (0.02) 0(61996140)
rs2001345 A>G 279 (0.99) 206 (1) 485 (0.99) 4 (0.01) 0 4 (0.01) 0(61996130)
SNPs marked in bold indicate polymorphic variants having MAF ≥ 1%
Figure 1. Schematic diagram showing 12 polymorphic SNPs spanning the proximal
promoter region of GH1. SNPs marked in bold letters indicate the polymorphic variants
that constitute the risk haplotype. Arrow below denotes negative stand with the nu-
cleotide positions at 5′ (at SNP rs2011732) and 3′ (at SNP position rs2001345) regions.
TSS, transcription start site.
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Table 3. Haplotype analysis of GH1 promoter SNPs rs2005171, rs11568828, rs2005172 and rs6171.
Frequency Unadjusted Adjusted
Group Haplotype Case Control OR (95% CI) P value OR (95% CI) P value
CAD (n = 299) vs
TAGA 0.037 0.0133 2.84 (1.04 − 7.77) 0.043 31.31 (1.33 − 8.29)∗ 0.011
Contro (n = 231)
CAD with Diabetes (n = 123) vs
TAGA 0.055 0.014 3.52 (1.24 − 10.01) 0.019 1.79 (0.42 − 7.61)# 0.43
Control (n = 198)
CAD with Hypertension
TAGA 0.038 0.019 2.79 (0.99 − 7.88) 0.054 1.73 (0.48 − 6.21) 0.40
(n = 166) vs Control (n = 192)
SNPs are sequentially located in each haplotype. CAD, coronary artery disease; CI, confidence interval; OR, odds ratio. ∗OR adjusted
for age, gender, smoking, diabetes and hypertension. #OR adjusted for age, gender, smoking and hypertension. OR adjusted for age,
gender, smoking and diabetes.
Table 4. Association of GHRd3 copy number with coronary artery disease.
GHRd3 n (%)
Participants 0-Copy 1-Copy 2-Copy aPobserved bPempirical
Controls 93 (35.8) 105 (48.6) 33 (61.1)
Cases 167 (64.2) 111 (51.4) 21 (38.9) < 0.00001 < 0.00001
aPobserved unadjusted P value calculated by Cochran–Armitage trend test. bPempirical
permutation P value calculated using 10000 Monte Carlo simulations.
after adjusting for age, gender, diabetes, hypertension and
smoking. There was significant association of the absence
of GHRd3 allele with CAD as compared to subjects carry-
ing 1 or 2 copies of the GHRd3 allele both before (OR 0.51,
95% CI: 0.36–0.73, P < 0.00001) and after (OR 0.48, 95%
CI: 0.30–0.76, P = 0.0014) correcting for confounders (ta-
ble 5). The percentage PAR for the absence of a copy of
GHRd3 allele was estimated to be 26.1% (95% CI: 12.8%–
37.4%). Chi-square analysis showed that there was no signif-
icant association between the copy number of GHRd3 allele
and GH1 gene promoter haplotypes.
Phenotype–genotype analysis
Multivariate analysis of plasma HDL-c levels with GHRd3
polymorphism showed that individuals with two copies of
GHRd3 had significantly higher levels of HDL-c (46.99
mg/dL) followed by those with one copy (41.47 mg/dL)
when compared to those with zero copy of the GHRd3 allele
(40.37 mg/dL) (P = 0.001). This diﬀerence remained sig-
nificant even after adjustment for age, gender and smoking
history. Subsequent to additional adjustment for statins, how-
ever, the association did not retain significance (P = 0.41)
(table 6). There was no significant association of GHRd3
copy number variants with other plasma lipids, namely TC,
TG, LDL-c levels and of GH1 variants with any of the plasma
lipids.
GH1 and stature
There was no significant diﬀerence in the mean height be-
tween CAD patients and controls both in males (166.04 cm
and 166.45 cm) and females (154.26 cm and 152.2 cm), re-
spectively. However, CAD patients with history of stroke
showed significantly lower mean height (−0.243 ± 0.106,
160.60 cm) as compared to CAD patients without stroke his-
tory (0.077 ± 0.047, 163.32 cm) (P = 0.006) or the con-
trols (−0.027 ± 0.051, 162.44 cm) (P = 0.073) after cor-
recting for age and gender (figure 2). The heterozygotes and
homozygotes for the minor alleles of the haplotype tagging
GH1 SNPs were combined for analysis for all four SNPs
due to low frequency. The SNPs rs2005171 (P = 0.014),
rs11568828 (P = 0.030) and rs2005172 (P = 0.023)
showed significant association with height (figure 3, a–d).
The GG genotype of rs2005171 was associated with decreas-
ing height while the AA genotype of rs11568828 and the
TT genotype of rs2005172 were associated with increasing
height. Regression analysis showed that 10 of the 12 poly-
morphic SNPs were able to explain up to nearly 2.3% of
variation in height in the overall data set. When analysis
was performed based on gender, 11 of the 12 SNPs con-
tributed significantly to 14.7% of variation in height in fe-
males (n = 133, P = 0.029) and up to 3.5% of the variation
in height in males (n = 343, P = 0.276).
Discussion
Our present study on an Asian Indian cohort has revealed
important leads that suggest a possible link between genetic
variations in the receptor and ligand of the pituitary growth
hormone with CVD and its comorbidities. Analysis of copy
number variations of GHRd3 allele revealed significant as-
sociation of genomic retention of exon 3 with CAD while
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Table 5. Assessment of diﬀerent genetic models for GHRd3 copy number.
∗Unadjusted †Adjusted
GHRd3
copy
Model number ‡ OR (95% CI) P value AIC OR (95% CI) P value §AIC
0 1.00 1.00
1 0.57 (0.39–0.83) 0.55 (0.34–0.89)
Codominant 2 0.33 (0.18–0.60) < 0.00001 712.1 0.29 (0.13–0.65) 0.0018 481.7
0 1.00 1.00
Dominant 1 – 2 0.5 (0.36–0.73) < 0.00001 713.3 0.48 (0.30–0.76) 0.0014 482
0 – 1 1.00 1.00
Recessive 2 0.43 (0.24–0.77) 0.0038 719 0.39(0.18–0.82) 0.011 485.7
0 – 2 1.00 1.00
Overdominant 1 0.71 (0.49–0.99) 0.044 723.4 0.68(0.43–1.08) 0.11 489.6
Logadditive – 0.57(0.44–0.75) < 0.0001 710.1 0.54(0.39–0.77) < 0.00001 479.7
∗P values were obtained from logistic regression modelling without any covariates. †P values were obtained
from logistic regression modelling after adjustment for age, gender, diabetes, hypertension and smoking.
‡OR, odds ratio, CI, confidence interval. §AIC, akaike information criterion.
Table 6. Multivariate analysis of GHRd3 copy number variation and plasma high den-
sity lipoprotein cholesterol levels.
Unadjusted Adjusted∗ Adjusted∗∗
GHRd3 mean ± mean ± mean ±
copy SEM# P SEM# P SEM# P
number (mg/di) value (mg/di) value (mg/di) value
3.7 ± 0.02 3.70 ± 0.02 3.63 ± 0.02
0 (40.37) (40.24) (37.86)
3.73 ± 0.02 3.72 ± 0.02 3.56 ± 0.03 0.06†
1 (41.47) 0.008‡ (41.10) 0.006† (35.21)
3.85 ± 0.04 3.85 ± 0.04 3.69 ± 0.06 0.41‡
2 (46.99) 0.001† (46.85) 0.001‡ (39.96)
# Log transformed mean ± SD for HDL-c has been provided with the re-transformed
means represented within brackets. SEM, standard error of mean. †Comparison of
GHRd3, 1 copy versus 2 copy deletion. ‡Comparison of GHRd3, 0 copy versus 2 copy
deletion. ∗Adjusted for age, gender and smoking. ∗∗Adjusted for age, gender, smoking
and statins.
Figure 2. Analysis of variance of disease status with standardized
height (height Z-score); mean height indicated in cm.
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Figure 3. Univariate analysis of height Z-score with the four haplotype tagging SNPs; mean height
indicated in cm.
deletion of the same region was associated with higher
plasma HDL-c levels. We identified 12 novel variants in the
promoter region of GH1 gene and a TAGA haplotype, con-
stituted by functional SNPs that showed significant associa-
tion with CAD alone or with CAD and diabetes when com-
pared to clinically matched controls. Further, three of these
promoter polymorphisms were significantly associated with
stature.
The GHR gene encodes for a transmembrane receptor
protein to which the growth hormone binds resulting in
the activation of the signal transduction pathway leading to
growth. There has been extensive discussions on the role of
GHRd3 in modulating GH response in growth-retarded chil-
dren with hormone deficiency (Jorge et al. 2006; Tauber et al.
2007) and in increased insulin secretion in healthy children
and in adolescents during puberty (Sorensen et al. 2009).
In the present study, the GHRd3 allele exhibited protective
eﬀect against CAD accompanied by higher levels of HDL-
c among subjects carrying the deletion allele after adjust-
ing for age, gender and smoking. However, this association
did not retain significance following adjustment for statins.
This trend needs to be confirmed on a larger cohort. In a
report on the response of short-term recombinant GH ther-
apy in GH deficient adults, it has been shown that patients
carrying at least one GHRd3 allele exhibited a significant in-
crease in HDL-c levels as compared to those lacking a copy
of the deletion (van der Klaauw et al. 2008), implicating
the critical role of growth hormone in regulating lipopro-
tein metabolism. Further, the GHRd3 allele has been found
to show a protective eﬀect against development of type 2 dia-
betes in adult life (Strawbridge et al. 2007). A marginal asso-
ciation was shown between GHRd3 and hypertension in lim-
ited number female stroke patients (Horan et al. 2006). The
strong association of full length exon 3 retention with CAD
and higher plasma level of an atheroprotective biomarker like
HDLc with GHRd3 in our cohort suggests that this variant
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can turn out to be a promising biomarker for CAD, worthy
of further pursuit with respect to its diagnostic and therapeu-
tic implications.
The GH1 promoter region is highly polymorphic and reg-
ulates the inter-individual variation in the levels of GH ex-
pression in a complex and interdependent manner (Horan et
al. 2003; Esteban et al. 2007). We identified 16 promoter
SNPs of which four were invariant. The promoter SNPs ex-
hibited moderate linkage disequilibrium. In addition, we dis-
covered 12 novel variants that have not been hitherto ob-
served in other populations. A recent report has suggested
that the genetic architecture of Asian Indian population, a
largely unexplored group to date, may possess discrete diﬀer-
ences from that of the HapMap populations (Indian Genome
Variation Consortium 2008).
We identified a risk haplotype, TAGA that was found to
be significantly associated with CAD. The four haplotype-
tagging SNPs were confirmed to be the most informative
markers in our cohort using multiple approaches. Three of
these four SNPs were significantly associated with standard-
ized height. Stepwise regression showed that the overall con-
tribution of 11 of the 12 polymorphic promoter variants was
14.7% in females and only 3.5% in males. The above finding
reiterates the complex nature of genetic regulation of stature
(Mullis 2005) with minimal, additive contribution of indi-
vidual SNPs with low penetrance. It is of interest to note
that the TAGA haplotype includes two functional SNPs, the
rs11568828 and rs2005172, which interact with the tran-
scription factors namely, pituitary specific factor (Pit 1), the
vitamin D responsive element (VDRE), the thyroid hormone
(T3) and retinoic acid (RA) (Suen et al. 1994; Cohen et al.
1996; Jimenez-Lara and Aranda 2000).
Epidemiological studies have shown a crucial link be-
tween adverse fetal environment and increased risk of
metabolic disorders and CVD in adult life (Barker 1995).
Administration of recombinant pituitary GH therapy in cases
of GH deficiency has shown a positive eﬀect on chronic car-
diac failure (Le Corvoisier et al. 2007), ischemic cardiomy-
opathy (Genth-Zotz et al. 1999), reversal of early atheroscle-
rotic changes (Pfeifer et al. 1999b) and lowering of hyperten-
sion, obesity (Vickers et al. 2002). An isolated report from
south India has shown that individuals who were small at
birth (weight < 2.5 kg at birth) or who were born to mothers
with low body weight (< 45 kg during pregnancy) showed
greater predisposition to heart disease in adult life, possi-
bly mediated by malnutrition (Stein et al. 1996). Significant
association has been reported between GH1 promoter hap-
lotypes and risk of hypertension and stroke (Horan et al.
2006). It has been previously shown that in a West African
population that elevated GH1 expression and GHR-mediated
GH responsiveness may be attributed to an adaptive response
against scarcity of food supply in this population (Millar et
al. 2008). Our present findings reveal that the promoter hap-
lotype of GH1 gene might be associated with risk of CAD
and diabetes in adult life. As our study was based on adult
participants, lack of proper record of birth weight informa-
tion in most of the patients and issues of recall bias were a
hindrance for further investigations in this direction.
The finding of lower mean standardized height among
CAD patients with stroke as compared to those without
stroke and healthy controls in our cohort is noteworthy. An
increased frequency of a GH1 promoter haplotype was re-
ported among hypertensive subjects and stroke patients as
compared to controls. They also observed an inverse cor-
relation between height and systolic blood pressure among
carriers of the GH1 risk haplotype (Horan et al. 2006). The
frequency of cases carrying the risk haplotype, TAGA, in our
study was very low, which precluded us from carrying out a
detailed analysis.
Limitations in the present study are that the sample size
is small. Also, the controls are on an average three years
younger than the probands. As it is critical to have controls
who are well matched to that of the cases, we will be testing
our initial study findings on a larger cohort of 1000 CAD pa-
tients and 1000 controls who are matched for age, gender as
well as ethnicity based on the mother tongue.
In conclusion, our preliminary study on a representative
Asian Indian population at high risk of CVD reveals an inter-
esting association between genetic variants in the GH1 pro-
moter region and its receptor with CAD and stature. In light
of the fact that Asian Indians have a small build, a unique fat
distribution and a lower threshold for established risk factors
that precipitate risk of CVD at an early age, the present find-
ings provide an interesting insight on the novel genetic ele-
ments relating to growth and development in impacting CVD
and its co-morbidities. Extended studies on a clinically well
defined cohort, with characterization of the complete GH1
gene and its receptor, supported by functional validation may
add yet another important dimension to the ongoing eﬀorts to
identify putative candidate genes that precipitate early pre-
disposition to CVD in the Asian Indian population.
Acknowledgements
We are grateful for the encouragement given by the Trustees of
TRI India and London towards the Indian Atherosclerosis Research
Study and the Thrombosis Research Institute India. This work was
supported by the Tata Social Welfare Trust, Garfield Weston Foun-
dation, Department of Biotechnology and the Elizabeth and Em-
manuel Kaye Foundation. We thank the doctors and management
of Narayana Hrudayalaya, Bangalore, India, and the Asian Heart
Institute and Research Center, Mumbai, India, for providing clini-
cal assistance. We thank all the staﬀ involved in cohort screening
and enrolment, data entry and the TRI administrative team for their
respective contributions and support provided for this study. We are
obliged to the patients, their family members and controls for par-
ticipating in our study.
References
Abramson J. H. 2004 WINPEPI (PEPI-for-Windows): computer
programs for epidemiologists. Epidemiol. Perspect. Innov. 1, 6.
Journal of Genetics, Vol. 89, No. 4, December 2010 445
Arindam Maitra et al.
Barker D. J. 1995 The fetal and infant origins of disease. Eur. J.
Clin. Invest. 25, 457–463.
Barrett J. C., Fry B., Maller J. and Daly M. J. 2005 Haploview: anal-
ysis and visualization of LD and haplotype maps. Bioinformatics
21, 263–265.
Binder G., Trebar B., Baur F., Schweizer R. and Ranke M. B.
2008 Homozygosity of the d3-growth hormone receptor poly-
morphism is associated with a high total eﬀect of GH on growth
and a low BMI in girls with Tumer syndrome. Clin. Endocrinol.
68, 567–572.
Blum W. F., Machinis K., Shavrikova E. P., Keller A., Stobbe H.,
Pfaeﬄe R. W. and Amselem S. 2006 The growth response to
growth hormone (GH) treatment in children with isolated GH de-
ficiency is independent of the presence of the exon 3-minus iso-
form of the GH receptor. J. Clin. Endocrinol. Metab. 91, 4171–
4174.
Bondanelli M., Ambrosio M. R., Onofri A., Bergonzoni A., Lavezzi
S., Zatelli M. C. et al. 2006 Predictive value of circulating
insulin-like growth factor I levels in ischemic stroke outcome.
J. Clin. Endocrinol. Metab. 91, 3928–3934.
Carrascosa A., Audi L., Esteban C., Fernandez-Cancio M., An-
daluz P., Gussinye M. et al. 2008 Growth hormone (GH) dose,
but not exon 3-deleted/full-length GH receptor polymorphism
genotypes, influences growth response to two-year GH therapy
in short small-for-gestational-age children. J. Clin. Endocrinol.
Metab. 93, 147–153.
Cittadini A., Cuocolo A., Merola B., Fazio S., Sabatini D., Nico-
lai E. et al. 1994 Impaired cardiac performance in GH-deficient
adults and its improvement after GH replacement. Am. J. Physiol.
267, E219–E225.
Climent V. E., Pico A., Sogorb F., Aznar S., Lip G. Y. and Marin F.
2006 Growth hormone therapy and the heart. Am. J. Cardiol. 97,
1097–1102.
Cohen L. E., Wondisford F. E. and Radovick S. 1996 Role of Pit-1
in the gene expression of growth hormone, prolactin, and thy-
rotropin. Endocrinol. Metab. Clin. North Am. 25, 523–540.
Esteban C., Audi L., Carrascosa A., Fernandez-Cancio M., Perez-
Arroyo A., Ulied A. et al. 2007 Human growth hormone (GH1)
gene polymorphism map in a normal-statured adult population.
Clin. Endocrinol. 66, 258–268.
Friedewald W. T., Levy R. I. and Fredrickson D. S. 1972 Estima-
tion of the concentration of low-density lipoprotein cholesterol
in plasma, without use of the preparative ultracentrifuge. Clin.
Chem. 18, 499–502.
Garcia-Aragon J., Lobie P. E., Muscat G. E., Gobius K. S., Norstedt
G. and Waters M. J. 1992 Prenatal expression of the growth hor-
mone (GH) receptor/binding protein in the rat: a role for GH in
embryonic and fetal development? Development 114, 869–876.
Genth-Zotz S., Zotz R., Geil S., Voigtlander T., Meyer J. and Darius
H. 1999 Recombinant growth hormone therapy in patients with
ischemic cardiomyopathy : eﬀects on hemodynamics, left ven-
tricular function, and cardiopulmonary exercise capacity. Circu-
lation 99, 18–21.
Greenacre M. J. 1984 Theory and applications of correspondence
analysis. Academic Press, London, UK.
Horan M., Millar D. S., Hedderich J., Lewis G., Newsway V.,
Mo N., Fryklund L. et al. 2003 Human growth hormone 1
(GH1) gene expression: complex haplotype-dependent influence
of polymorphic variation in the proximal promoter and locus
control region. Hum. Mutat. 21, 408–423.
Horan M., Newsway V., Yasmin N., Lewis M. D., Easter T. E., Rees
D. A. et al. 2006 Genetic variation at the growth hormone (GH1)
and growth hormone receptor (GHR) loci as a risk factor for hy-
pertension and stroke. Hum. Genet. 119, 527–540.
Hubbard T. J., Aken B. L., Beal K., Ballester B., Caccamo M., Chen
Y. 2007 Nucleic Acids Res. 35 (Database issue), D610–D617.
Indian Genome Variation Consortium 2008 Genetic landscape of
the people of India: a canvas for disease gene exploration. J.
Genet. 87, 3–18.
Jensen R. B., Vielwerth S., Larsen T., Greisen G., Leﬀers H. and
Juul A. 2007 The presence of the d3-growth hormone receptor
polymorphism is negatively associated with fetal growth but pos-
itively associated with postnatal growth in healthy subjects. J.
Clin. Endocrinol. Metab. 92, 2758–2763.
Jimenez-Lara A. M. and Aranda A. 2000 Interaction of vitamin D
and retinoid receptors on regulation of gene expression. Horm.
Res. 54, 301–305.
Johnson R., McNutt P., MacMahon S. and Robson R. 1997 Use of
the Friedwald formula to estimate LDL-cholesterol in patients
with chronic renal failure on dialysis. Clin. Chem. 43, 2183–
2184.
Jorge A. A., Marchisotti F. G., Montenegro L. R., Carvalho L. R.,
Mendonca B. B. and Arnhold I. J. 2006 Growth hormone (GH)
pharmacogenetics: influence of GH receptor exon 3 retention or
deletion on first-year growth response and final height in patients
with severe GH deficiency. J. Clin. Endocrinol. Metab. 91, 1076–
1080.
Ko J. M., Park J. Y. and Yoo H. W. 2009 Common exon 3 polymor-
phism of the GH receptor (GHR) gene and eﬀect of GH therapy
on growth in Korean children with idiopathic short stature (ISS).
Clin. Endocrinol. 70, 82–87.
Kumar N. K. 2006 Bioethics activities in India. East Mediterr.
Health J. 12 suppl 1, S56–S65.
Langenberg C., Hardy R., Breeze E., Kuh D. and Wadsworth M. E.
2005 Influence of short stature on the change in pulse pressure,
systolic and diastolic blood pressure from age 36 to 53 years: an
analysis using multilevel models. Int. J. Epidemiol. 34, 905–913.
Le Corvoisier P., Hittinger L., Chanson P., Montagne O., Macquin-
Mavier I., Maison P. 2007 Cardiac eﬀects of growth hormone
treatment in chronic heart failure: A meta-analysis. J. Clin. En-
docrinol. Metab. 92, 180–185.
McCarron P., Greenwood R., Ebrahim S., Elwood P. and Smith
G. D. 2000 Adult height is inversely associated with ischaemic
stroke. The Caerphilly and Speedwell collaborative studies. J.
Epidemiol. Commun. Health 54, 239–240.
Millar D. S., Lewis M. D., Horan M., Newsway V., Rees D. A.,
Easter T. E. et al. 2008 Growth hormone (GH1) gene variation
and the growth hormone receptor (GHR) exon 3 deletion poly-
morphism in a West-African population. Mol. Cell Endocrinol.
296, 18–25.
Miller S. A., Dykes D. D. and Polesky H. F. 1988 A simple salting
out procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res. 16, 1215.
Minczykowski A., Gryczynska M., Ziemnicka K., Czepczynski R.,
Sowinski J. and Wysocki H. 2005 The influence of growth hor-
mone (GH) therapy on cardiac performance in patients with
childhood onset GH deficiency. Growth Horm. IGF Res. 15, 156–
164.
Mullis P. E. 2005 Genetic control of growth. Eur. J. Endocrinol.
152, 11–31.
PfaﬄM. W. A 2001 New mathematical model for relative quantifi-
cation in real-time RT-PCR. Nucleic Acids Res. 29, 2002–2007.
Pfeifer M., Verhovec R. and Zizek B. 1999a Growth hormone (GH)
and atherosclerosis: changes in morphology and function of ma-
jor arteries during GH treatment. Growth Horm. IGF Res. 9,
suppl. 25–30.
Pfeifer M., Verhovec R., Zizek B., Prezelj J., Poredos P. and
Clayton R. N. 1999b Growth hormone (GH) treatment reverses
446 Journal of Genetics, Vol. 89, No. 4, December 2010
Association of GH1 and GHR gene polymorphisms with CAD
early atherosclerotic changes in GH-deficient adults. J. Clin. En-
docrinol. Metab. 84, 453–457.
Reed D. M., Resch J. A., Hayashi T., MacLean C. and Yano K. A.
1988 Prospective study of cerebral artery atherosclerosis. Stroke
19, 820–825.
Rodriguez S., Gaunt T. R. and Day I. N. 2007 Molecular genetics
of human growth hormone, insulin-like growth factors and their
pathways in common disease. Hum. Genet. 122, 1–21.
Sole X., Guino E., Valls J., Iniesta R. and Moreno V. 2006
SNPStats: a web tool for the analysis of association studies.
Bioinformatics 22, 1928–1929.
Song Y. M., Smith G. D. and Sung J. 2003 Adult height and cause-
specific mortality: a large prospective study of South Korean
men. Am. J. Epidemiol. 158, 479–485.
Sorensen K., Aksglaede L., Munch-Andersen T., Aachmann-
Andersen N. J., Leﬀers H., Helge J. W. et al. 2009 Impact of the
growth hormone receptor exon 3 deletion gene polymorphism on
glucose metabolism, lipids, and insulin-like growth factor-I lev-
els during puberty. J. Clin. Endocrinol. Metab. 94, 2966–2969.
Stein C. E., Fall C. H., Kumaran K., Osmond C., Cox V. and Barker
D. J. 1996 Fetal growth and coronary heart disease in south India.
Lancet 348, 1269–1273.
Strawbridge R. J., Karvestedt L., Li C., Efendic S., Ostenson C. G.,
Gu H. F. and Brismar K. 2007 GHR exon 3 polymorphism: as-
sociation with type 2 diabetes mellitus and metabolic disorder.
Growth Horm. IGF Res. 17, 392–398.
Suen C. S., Yen P. M. and Chin W. W. 1994 In vitro transcriptional
studies of the roles of the thyroid hormone (T3) response ele-
ments and minimal promoters in T3-stimulated gene transcrip-
tion. J. Biol. Chem. 269, 1314–1322.
Tauber M., Ester W., Auriol F., Molinas C., Fauvel J., Caliebe J.
et al. 2007 GH responsiveness in a large multinational cohort of
SGA children with short stature (NESTEGG) is related to the
exon 3 GHR polymorphism. Clin. Endocrinol. 67, 457–461.
van der Klaauw A. A., van der Straaten T., Baak-Pablo R., Biermasz
N. R., Guchelaar H. J., Pereira A. M. et al. 2008 Influence of
the d3-growth hormone (GH) receptor isoform on short-term and
long-term treatment response to GH replacement in GH-deficient
adults. J. Clin. Endocrinol. Metab. 93, 2828–2834.
Vickers M. H., Ikenasio B. A. and Breier B. H. 2002 Adult growth
hormone treatment reduces hypertension and obesity induced by
an adverse prenatal environment. J. Endocrinol. 175, 615–623.
World Medical Association declaration of Helsinki 1997 Recom-
mendations guiding physicians in biomedical research involving
human subjects. JAMA 277, 925–926.
Received 26 March 2010, in revised form 8 June 2010; accepted 9 July 2010
Published on the Web: 6 December 2010
Journal of Genetics, Vol. 89, No. 4, December 2010 447
